Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies
- PMID:33895414
- DOI: 10.1016/j.jgar.2021.04.001
Resistance to ceftazidime/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies
Abstract
Objectives: Ceftazidime/avibactam (CAZ-AVI), approved in 2015, is an important first-line option for Klebsiella pneumoniae carbapenemase-producing Enterobacterales (KPC-E). Although still uncommon, resistance to CAZ-AVI has emerged and may represent a serious cause of concern.
Methods: We performed a systematic literature review of clinical and microbiological features of infections and colonisations by CAZ-AVI-resistant KPC-E, focused on the in vivo emergence of CAZ-AVI resistance in different clinical scenarios.
Results: Twenty-three papers were retrieved accounting for 42 patients and 57 isolates, mostly belonging to K. pneumoniae ST258 harbouring D179Y substitution in the KPC enzyme. The USA, Greece and Italy accounted for 80% of cases. In one-third of isolates resistance was not associated with previous CAZ-AVI exposure. Moreover, 20% of the strains were colistin-resistant and 80% were extended-spectrum β-lactamase (ESBL)-producers. The majority of infected patients had severe underlying diseases (39% cancer, 22% solid-organ transplantation) and 37% died. The abdomen, lung and blood were the most involved infection sites. Infections by CAZ-AVI-resistant strains were mainly treated with combination therapy (85% of cases), with meropenem being the most common (65%) followed by tigecycline (30%), gentamicin (25%), colistin (25%) and fosfomycin (10%). Despite the emergence of resistance, 35% of patients received CAZ-AVI.
Conclusion: Taken together, these data highlight the need for prompt susceptibility testing including CAZ-AVI for Enterobacterales, at least in critical areas. Resistance to CAZ-AVI is an urgent issue to monitor in order to improve both empirical and targeted CAZ-AVI use as well as the management of patients with infections caused by CAZ-AVI-resistant strains.
Keywords: Antimicrobial resistance; Antimicrobial stewardship; Ceftazidime/avibactam; Enterobacterales; KPC; Last-resort antibiotics.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Similar articles
- Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.Davido B, Crémieux AC, Vaugier I, Gatin L, Noussair L, Massias L, Laurent F, Saleh-Mghir A.Davido B, et al.Int J Antimicrob Agents. 2023 Jan;61(1):106702. doi: 10.1016/j.ijantimicag.2022.106702. Epub 2022 Dec 5.Int J Antimicrob Agents. 2023.PMID:36476965
- In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, Viale P, Re MC, Ambretti S.Gaibani P, et al.Int J Infect Dis. 2017 Dec;65:1-3. doi: 10.1016/j.ijid.2017.09.017. Epub 2017 Sep 22.Int J Infect Dis. 2017.PMID:28951106
- Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations inblaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.Giddins MJ, Macesic N, Annavajhala MK, Stump S, Khan S, McConville TH, Mehta M, Gomez-Simmonds A, Uhlemann AC.Giddins MJ, et al.Antimicrob Agents Chemother. 2018 Feb 23;62(3):e02101-17. doi: 10.1128/AAC.02101-17. Print 2018 Mar.Antimicrob Agents Chemother. 2018.PMID:29263067Free PMC article.
- Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.Zhen S, Wang H, Feng S.Zhen S, et al.Infection. 2022 Dec;50(6):1409-1423. doi: 10.1007/s15010-022-01876-x. Epub 2022 Jul 4.Infection. 2022.PMID:35781869Review.
- Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of Gram-negative bacterial infections: a systematic review and meta-analysis.Zhong H, Zhao XY, Zhang ZL, Gu ZC, Zhang C, Gao Y, Cui M.Zhong H, et al.Int J Antimicrob Agents. 2018 Oct;52(4):443-450. doi: 10.1016/j.ijantimicag.2018.07.004. Epub 2018 Aug 31.Int J Antimicrob Agents. 2018.PMID:30012440Review.
Cited by
- Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022).Boattini M, Bianco G, Bastos P, Comini S, Corcione S, Almeida A, Costa C, De Rosa FG, Cavallo R.Boattini M, et al.Eur J Clin Microbiol Infect Dis. 2024 Jan;43(1):155-166. doi: 10.1007/s10096-023-04712-8. Epub 2023 Nov 21.Eur J Clin Microbiol Infect Dis. 2024.PMID:37985552Free PMC article.
- Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.Findlay J, Poirel L, Bouvier M, Gaia V, Nordmann P.Findlay J, et al.Eur J Clin Microbiol Infect Dis. 2023 May;42(5):639-644. doi: 10.1007/s10096-023-04582-0. Epub 2023 Mar 6.Eur J Clin Microbiol Infect Dis. 2023.PMID:36877262Free PMC article.
- Effects of Secondary Amine and Molecular Weight on the Biological Activities of Cationic Amphipathic Antimicrobial Macromolecules.Shao Z, Luo H, Nguyen THQ, Wong EHH.Shao Z, et al.Biomacromolecules. 2024 Oct 14;25(10):6899-6912. doi: 10.1021/acs.biomac.4c01137. Epub 2024 Sep 23.Biomacromolecules. 2024.PMID:39312184
- Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals.Camargo CH, Yamada AY, de Souza AR, Cunha MPV, Ferraro PSP, Sacchi CT, Dos Santos MB, Campos KR, Tiba-Casas MR, Freire MP, Barretti P.Camargo CH, et al.Sci Rep. 2023 Sep 5;13(1):14603. doi: 10.1038/s41598-023-41903-x.Sci Rep. 2023.PMID:37670032Free PMC article.
- [Epidemiological Analysis of Carbapenem-Resistant Enterobacteriaceae Strains in the Clinical Specimens of a Hospital].Yuan Y, Zhou D, Liao QF, Tang SS, He C.Yuan Y, et al.Sichuan Da Xue Xue Bao Yi Xue Ban. 2023 May;54(3):602-607. doi: 10.12182/20230560203.Sichuan Da Xue Xue Bao Yi Xue Ban. 2023.PMID:37248591Free PMC article.Chinese.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical